These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24813344)

  • 1. Definition of biochemical success following primary whole gland prostate cryoablation.
    Levy DA; Ross AE; ElShafei A; Krishnan N; Hatem A; Jones JS
    J Urol; 2014 Nov; 192(5):1380-4. PubMed ID: 24813344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
    Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
    Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
    Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
    J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary cryoablation nadir prostate specific antigen and biochemical failure.
    Levy DA; Pisters LL; Jones JS
    J Urol; 2009 Sep; 182(3):931-7. PubMed ID: 19616226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
    Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
    J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
    Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
    J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
    Dhar N; Ward JF; Cher ML; Jones JS
    BJU Int; 2011 Aug; 108(4):508-12. PubMed ID: 21722288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate.
    Elshafei A; Kovac E; Dhar N; Levy D; Polascik T; Mouraviev V; Yu C; Jones JS
    Prostate; 2015 Sep; 75(13):1447-53. PubMed ID: 26172607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
    Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS
    J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome.
    Ng CK; Moussa M; Downey DB; Chin JL
    J Urol; 2007 Oct; 178(4 Pt 1):1253-7; discussion 1257. PubMed ID: 17698104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
    Oishi M; Gill IS; Tafuri A; Shakir A; Cacciamani GE; Iwata T; Iwata A; Ashrafi A; Park D; Cai J; Desai M; Ukimura O; Bahn DK; Abreu AL
    J Urol; 2019 Dec; 202(6):1188-1198. PubMed ID: 31347953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of disease burden on cryoablation prostate-specific antigen outcomes.
    Levy DA; Li J; Jones S
    Urology; 2010 Feb; 75(2):478-81. PubMed ID: 19963251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
    Thüroff S; Chaussy C
    J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate.
    Pitman M; Shapiro EY; Hruby GW; Truesdale MD; Cheetham PJ; Saad S; Katz AE
    Prostate; 2012 Dec; 72(16):1802-8. PubMed ID: 22618738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
    Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
    Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage prostate cryoablation: initial results from the cryo on-line data registry.
    Pisters LL; Rewcastle JC; Donnelly BJ; Lugnani FM; Katz AE; Jones JS
    J Urol; 2008 Aug; 180(2):559-63; discussion 563-4. PubMed ID: 18554664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.
    Ganzer R; Robertson CN; Ward JF; Brown SC; Conti GN; Murat FJ; Pasticier G; Rebillard X; Thuroff S; Wieland WF; Blana A
    BJU Int; 2011 Oct; 108(8 Pt 2):E196-201. PubMed ID: 21332907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
    Chen PY; Chiang PH; Liu YY; Chuang YC; Cheng YT
    Int J Urol; 2018 Jun; 25(6):615-620. PubMed ID: 29756298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.